Humans possess three distinct genes for relaxin, termed RLN1 (H1 relaxin), RLN2 (H2 relaxin), and RLN3 (H3 relaxin; 1,2). All insulin-and relaxin-like peptides share a homologous molecular structure that defines them as members of the relaxin peptide family (1, 2). Each mature peptide (ϳ6 -7 kDa) has an internal A-chain disulfide bond. The A and B chains are joined by two interchain disulfide bonds (2). Relaxin is classically known as a reproductive hormone with peak levels circulating during pregnancy (2). However, in the past 20 years, studies have broadened the scope for relaxin biology to a number of paradigms. It is now considered a pleiotropic hormone with functions in the cardiovascular and central nervous systems, in neovascularization, extracellular matrix (ECM) and connective tissue remodeling believed to be mediated by matrix metalloproteinases (MMPs), and as a factor associated with cancer (2-5).
Humans possess three distinct genes for relaxin, termed RLN1 (H1 relaxin), RLN2 (H2 relaxin), and RLN3 (H3 relaxin; 1,2). All insulin-and relaxin-like peptides share a homologous molecular structure that defines them as members of the relaxin peptide family (1, 2) . Each mature peptide (ϳ6 -7 kDa) has an internal A-chain disulfide bond. The A and B chains are joined by two interchain disulfide bonds (2) . Relaxin is classically known as a reproductive hormone with peak levels circulating during pregnancy (2) . However, in the past 20 years, studies have broadened the scope for relaxin biology to a number of paradigms. It is now considered a pleiotropic hormone with functions in the cardiovascular and central nervous systems, in neovascularization, extracellular matrix (ECM) and connective tissue remodeling believed to be mediated by matrix metalloproteinases (MMPs), and as a factor associated with cancer (2) (3) (4) (5) .
The human H2 relaxin hormone has been reported as a peptide implicated in a number of neoplasias originating in the endometrium (6) , breast (7) , and thyroid (8) . Moreover, there is growing evidence in the literature supporting a role for relaxin peptides in the prostate (the main source of relaxin in the male) (4, 9, 10) , and incidentally, in prostate cancer (9, 11) . We recently reported that lentiviral (LV)-engineered overexpression of H2 relaxin from PC-3 prostate xenograft tumors exhibited increased growth compared to controls (12) . We attributed this relaxin-induced growth to enhanced angiogenesis, which was evidenced by upregulated vascular endothelial growth factor (VEGF) transcript and increased tumoral microvessel density (12) .
Relaxin family members have a highly conserved receptor binding domain (RBD) located on the Bchain (2) . H1, H2, H3 relaxin hormones and their orthologs sequenced to date have the Arg-X-X-X-Arg-X-X-Ile motif at positions B13, B17, and B20, with the exception of porcine relaxin, which has a valine residue at B20 (2) . This RBD motif is essential for relaxin activity and receptor binding (13, 14) . Bullesbach et al. (1992) confirmed the importance of these amino acids by synthesizing H2 relaxin derivatives with B13 and B17 arginines replaced with other amino acid residues (13). When a dilysine H2 relaxin (at sites B13, B17) was tested in a receptor binding assay, it exhibited ϳ2200-fold lower affinity than that of WT H2 relaxin (13). Later studies determined that substitution of the isoleucine residue in WT H2 at B20 with alanine reduced receptor binding by 3 orders of magnitude, which led to the model that relaxin binds to its receptor as a trivalent structure (14) .
In the current report, we hypothesized that substitution of the B13 and B17 arginine residues within the RBD with lysine residues would allow the peptide to retain partial affinity for the receptor, while not inducing significant signal transduction. Therefore, this study reports the in vitro characterization of this H2 relaxin derivative (⌬H2) and examines its function in vivo using a prostate tumor model. We observed for the first time here that ⌬H2 relaxin exhibits antagonistic properties both in vitro and in vivo by interfering with H2 relaxin-induced signaling and impairing prostate xenograft tumor growth.
MATERIALS AND METHODS

Cell lines and culture conditions
Cell lines were obtained from the American Type Culture Collection (ATCC) (Rockville, MD, USA). The human embryonic kidney cell line, 293T, the human prostate cancer cell line, PC-3, and the human monocytic cell line, THP-1, were cultured as described previously (12, 15) . The human prostate cancer cell line, LNCaP, was cultured in RPMI 1640 medium. All culture media (Sigma, Oakville, ON, Canada) were supplemented with 10% fetal calf serum (FCS; Gemini Bio-Products, Woodland, CA, USA), 100 U/mL penicillin and 10 g/mL streptomycin. Cells were cultured at 37°C in a humidified atmosphere with 5% CO 2 .
Engineering of mutant H2 relaxin (⌬H2) and construction of lentiviral vectors
The H2 relaxin cDNA present in a cytomegalovirus (CMV)-H2-IRES-eGFP expression cassette (12, 16) was mutated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA). The nucleotides encoding the two arginine residues of the classic receptor binding motif were replaced with nucleotides that encode lysine residues (Fig. 1) . This cDNA was denoted ⌬H2. LVs were constructed to engineer expression of the CMV-H2-IRES-eGFP, CMV-⌬H2-IRES-eGFP and CMV-IRES-eGFP cassettes in the pHR' LV backbone (12) . LV virions constructed with one of three gene transfer vectors (pHR-cPPT-CMV-H2-IRES-eGFP-WPRE, pHRcPPT-CMV-⌬H2-IRES-eGFP-WPRE or pHR-cPPT-CMV-IRESeGFP-WPRE) were produced, concentrated, titered, and analyzed for eGFP expression as described previously (17) . Concentrated LV titers ranged from 1 ϫ 10 8 -5 ϫ 10 8 productive 293T infectious units/mL.
Generation of engineered PC-3 and 293T cell lines
PC-3 cells were engineered and clonally selected to express luciferase (PC3-Luc; ref 12). PC3-Luc and 293T cell lines were transduced with viral supernatants (LV-H2/eGFP, LV-⌬H2/ eGFP, or LV-eGFP) for 24 h, followed by a change in culture medium. The upper 10% of these eGFP-expressing cells were sorted using a MoFlo cytometer [Cytomation Inc., Princess Margaret Hospital (PMH), Toronto, Canada]. Populations of PC3-Luc cells expressing either eGFP alone, or in a bicistronic format with either H2 or ⌬H2 relaxin, were characterized to be ϳ85% positive for fluorescent protein expression (data not shown). These cell populations were termed PC3-Luc-eGFP, PC3-Luc-H2/eGFP and PC3-Luc-⌬H2/eGFP. LVinfected 293T cell populations were also selected that were ϳ50% and 90% for eGFP-positive expression. Cell cultures were termed 293T-H2/eGFP(50%), 293T-⌬H2/eGFP(50%), 293T-⌬H2/eGFP(90%), and 293T-eGFP(50%). All plots were gated on live cells by exclusion of 7-AAD (Sigma) labeled dead cells.
Measurement of relaxin expression and bioactivity
H2 relaxin expression from the transduced PC3-Luc and 293T cells lines was confirmed by ELISA analysis. Transduced PC3-Luc and 293T cell lines were seeded in serum-free media at a density of 3.5 ϫ 10 6 and 5 ϫ 10 6 cells in 10-cm-diameter plates. Samples were harvested at the specified time, lyophilized, and resuspended in 1/10th the original volume. To determine the amount of H2 relaxin peptide released into the cell culture medium, a recombinant human H2 relaxinspecific direct sandwich ELISA was performed as described previously (12, 16) .
To confirm the biological activity of the H2 and ⌬H2 relaxins, the cAMP Biotrak E1A System was employed (Amersham Biosciences) as described (15, 16) . For measurement bioactivity from conditioned medium (CM), 20 l from each concentrated sample was added to THP-1 cells. For measurement cAMP levels from the LV-infected PC3-Luc cells, 1 ϫ 10 5 cells were seeded in a 96-well plate and equilibrated for 2 h before cAMP was measured. Levels of cAMP from 293T-LGR7 Figure 1 . Amino acid modifications within the B-chain of human H2 relaxin by in vitro mutagenesis. A) Schematic depicting the heterodimeric structure of H2 relaxin containing the A-and B-chains connected by two disulfide bridges and the receptor binding domain (RBD; consisting of amino acids B13, B17, and B20) present on the B-chain. B) Amino acid and nucleotide sequences of the RBDs of WT H2 before and after (⌬H2 relaxin) in vitro mutagenesis. C) A schematic of LV-cPPT-CMV-⌬H2-IRES-eGFP-WPRE (LV-⌬H2/eGFP) used in this study. Long terminal repeat (LTR): long-terminal repeat; sd: splice donor; RRE: rev response element; SA: splice acceptor; cPPT: central polypurine tract; CMV: CMV promoter; WPRE: woodchuck hepatitis virus posttranscriptional regulatory element; IRES: encephalomyocarditis virus internal ribosomal entry site; eGFP: enhanced green fluorescent protein; SIN: self-inactivating LTR.
cell cultures (18, 19) were measured after incubation with 15 L of unconcentrated CM from LV-infected 293T cell cultures.
The THP-1 cAMP assay was also adapted for an H2 relaxin competitive assay. All steps remained consistent with previous assays with the exception that THP-1 cells were coincubated with 0.4 ng recombinant H2 relaxin (rH2; gift from Elaine Unemori; BAS Medical, Inc, San Francisco, CA, USA) and varying volumes (1, 3, 6 L) of concentrated CM from LV-infected 293T cell cultures. Total cAMP (intra-and extracellular) was measured for all experiments.
Preparation of biotin-X-X-rhH2 (bH2)
Human recombinant relaxin was labeled with 6-(Biotinamidocaproylamido)caproic acid N-hydroxysuccinimide ester (Biotin-X-X-NHS, MW 567.70; Sigma-Aldrich, Saint Louis, MO, USA). Briefly, 5 g of rH2 was added at a 1:20 M ratio with Biotin-X-X-NHS (reconstituted in dimethylformamide at 25 mg/mL) in a total volume of 250 l of PBS (pH 7.3) on ice for 1.5 h. The reaction was quenched by the addition of 1 l of 1M Tris-HCl (pH 8.0). The product was then dialyzed in 500 mL of PBS at RT overnight to remove uncoupled biotinylation reagent in a 3500 Da MW cut-off dialysis chamber (Elutatube Dialysis Kit; Fermentas, Burlington, ON, Canada). The final product was aliquoted and stored at -20°C until use. To confirm that bH2 did not differ in biological activity from rH2, 0.4 ng of each was subjected to the THP-1 cAMP assay as described above. Bioactivities of bH2 and rH2 remained virtually the same with demonstrated cAMP levels of 316 Ϯ 7.5 and 307 Ϯ 9.2 fmol/well, respectively (data not shown).
Flow cytometry-based relaxin binding assay
To optimize collection of recombinant ⌬H2 peptide for this assay, single-cell clones of LV-infected 293T cell cultures were isolated. Clones were confirmed by flow cytometry measuring eGFP fluorescence (as above) and selected based on highest expression. 293T-eGFP#3, 293T-⌬H2/eGFP#6, 293T-H2/ eGFP#3 cell cultures were seeded in 15-cm plates in complete medium overnight, refreshed with Dulbecco's Modified Eagle Medium (DMEM) medium containing 2% FCS after 24 h, and incubated for an additional 48 h. At this point, CM were collected for assays. H2 relaxin levels in unconcentrated CM from 293T-eGFP#3, 293T-⌬H2/eGFP#6, 293T-H2/eGFP#3 cell cultures were approximated by the H2 ELISA to be 0, 1, and 4 ng/mL (data not shown).
293T-LGR7 cells (18, 19) To determine whether mouse relaxins can bind to human LGR7, relative affinity of mouse relaxin and mouse relaxin-3 hormone were also measured in parallel. CM containing LV-engineered recombinant mouse relaxin and mouse relaxin-3 were prepared as described previously (19) . The flow cytometry-based binding assay for mouse relaxins was performed as above with the following modification: 293T-LGR7 cells were preincubated with CM (diluted 2-fold, 5-fold, and 20-fold) for 5 min at RT before addition of 10 ng of bH2. As above, the addition of controls containing bH2, rH2, and CM containing human H2 relaxin were also included.
Cell proliferation assays
Two assays were employed to measure cell proliferation. PC3-Luc-eGFP, PC3-Luc-H2/eGFP, and PC-3-Luc-⌬H2/eGFP cells were plated in triplicate at 1 ϫ 
PC3-Luc human prostate tumor model in NOD/SCID mice
Six-to eight-week old male NOD/SCID mice (The Jackson Laboratory; Bar Harbor, ME, USA) were maintained under an approved UHN protocol. Groups consisted of NOD/SCID mice injected with 2 ϫ 10 6 PC3-Luc-H2/eGFP, PC3-Luc-⌬H2/eGFP, or PC3-Luc-eGFP cells suspended in 200 l of Matrigel (BD; nϭ6 or 7 animals/ group). Injections were performed s.c. into the dorsal right flank of NOD/SCID mice. Tumors were measured weekly by calipers and tumor volume approximated (l x w x d), as described previously (12) . At weeks 9 and 11, animals underwent whole-body noninvasive bioluminescence imaging (BLI) to examine PC3-Luc cell biodistribution (12) . After sacrificing animals, blinded autopsies were performed to examine for metastatic events. To confirm that the metastatic tissue was of PC3-Luc origin, tissue was placed in a 6-well dish, incubated in luciferin, and imaged (12) . Tumors were harvested and examined for eGFP expression (12) . Following imaging, tumors were subsequently separated into equal halves. One half was sectioned, paraffin-embedded, and stained with anti-mouse CD31 (PE-CAM-1). The other half was homogenized in 1 mL of sterile PBS for collection of tumor cell lysates and total RNA for analysis of gelatinase expression by gelatin zymography and LGR7 and VEGF isoform expression by reverse transcriptasepolymerase chain reaction (RT-PCR), respectively (see Ref 12 for all methods). To study the effect of relaxin on microvessel dilation, microvessel area (MVA) was measured as described previously (20) . Briefly, leveled sections (nϭ2 to 4) within each tumor were evaluated in a blinded fashion using a Carl Zeiss Axioskop 2 microscope. At ϫ100 magnification, 9 -12 of the largest CD31-stained MVs were identified, and subsequently photomicrographed at ϫ400 magnification using the Axiocam MRc camera. Area, diameter and MV length (m) were measured using the length measurement tool of the Axiovision 3.1 software (Carl Zeiss). For plasma osmolality readings, 100 -200 L of blood was collected in heparin (heparin sodium, 1000 USP units/mL; Hepalean) and sent for analysis (Animal Health Laboratory, Department of Pathobiology, University of Guelph).
LNCaP human prostate tumor model in NOD/SCID mice
LNCaP cells were transduced with LV supernatants (LV-H2-IRES-eGFP, LV-⌬H2-IRES-eGFP, or LV-eGFP) to generate LV-infected LNCaP cell cultures, analogous to methods described for PC3-Luc cells. Cell lines (ϳ85% eGFP positive) were termed LNCaP-H2/eGFP, LNCaP-⌬H2/eGFP, and LNCaP-eGFP. H2 and ⌬H2 relaxin expression and bioactivity were confirmed by employing the H2 relaxin ELISA and the THP-1 cAMP assay (as described above). Groups consisted of 5-wk-old female NOD/SCID mice injected with 6 ϫ 10 6 LNCaP-H2/eGFP, LNCaP-⌬H2/eGFP, and LNCaP-eGFP cells (nϭ8 animals/ group) suspended in 200 L of Matrigel (BD) into the dorsal right flank. After 14 wk, blinded autopsies on mice were performed to examine for metastases. Tumors were harvested, imaged, and weighed as described above.
PC3-luc soft agarose colony assay
Powdered F12 Nutrient mixture (Life Technologies, Inc., Gaithersburg, MD, USA) was prepared as a sterile 2 ϫ complete medium and buffered with sodium bicarbonate to pH 7.67. Six-well culture dishes were coated with 1.5 mL/well of 1:1 mixture of 0.8% sterile low melting agarose (NuSieve GTG agarose; BioWhittaker Molecular Applications, Rockland, ME, USA) mixed with 2 ϫ F12 medium (supplemented with 20% FCS, 200 U/mL penicillin; 20 g/mL streptomycin) and stored at 4°C to solidify. Then 1.5 mL of varying dilutions of PC3-Luc-H2/eGFP, PC3-Luc-⌬H2/eGFP, or PC3-Luc-eGFP cells (ranging from 100 to 1000 cells/mL) suspended in F12/ 0.4% agarose solution were applied in triplicate to the coated 6-well plates. Wells were replenished with fresh F12/0.4% agarose solution every 3 or 4 days for 5 wk. Colony spheres were counted, measured, and imaged using a Nikon TE200 inverted microscope mounted with a Hamamatsu ORCA 100 camera and analyzed with SimplePCI version 3.1 software (Compix Inc., Sewickley, PA, USA).
Intratumoral delivery of lentiviral vectors to PC3-Luc tumors
NOD/SCID male mice (nϭ15) were injected in the dorsal right flank with 3 ϫ 10 6 PC3-Luc cells suspended in 200 l of Matrigel (BD). When tumors reached ϳ1 cm 3 , animals were divided into three groups to equally distribute age and weight of the mice. Every 3 or 4 days for 18 days, tumors were injected in four random sites with 5 l of concentrated LV suspension (LV-H2/eGFP, LV-⌬H2/eGFP, LV-eGFP) per site using a 25 l Hamilton microsyringe (totalϭϳ4ϫ10 6 infectious units). Tumors were measured on the day of each intratumoral LV delivery by calipers. At day 18, animals underwent whole-body noninvasive BLI and a complete autopsy to examine for PC3-Luc cell biodistribution (12) . After euthanizing animals, tumors were harvested and examined for eGFP expression (12) .
Statistical analysis
Differences between two treatment groups were statistically analyzed using a two-tailed, independent samples t test. Differences among three or more groups were analyzed using a one-way ANOVA test. To account for multiple comparisons testing of the tumor volume, a Bonferroni t test within each time point was performed to make adjustment to the P values. Plasma osmolality data were analyzed using a median two-sample test (SAS). Error bars indicate the se, and significance is indicated by an asterisk when P Յ 0.05. Statistical analyses were performed under consultation with the Clinical Studies Resource Centre, UHN (Toronto, Canada).
RESULTS
Generation of LVs and characterization of transduced cell lines
The H2 relaxin cDNA was subjected to in vitro sitedirected mutagenesis to replace the nucleotides encoding arginines at B13 and B17 with nucleotides encoding lysine residues (Fig. 1A,B) . The other amino acid (isoleucine at B20), critical for receptor binding, was left intact. To produce ⌬H2 relaxin, a novel recombinant LV was constructed (Fig. 1C) .
Concentrated CM from PC3-Luc-H2/eGFP, and 293T-H2/eGFP(50%) samples contained significant levels of H2 relaxin compared to basal or undetectable levels in the PC3-eGFP and 293T-eGFP(50%) samples, respectively ( Fig. 2A,B) . ⌬H2 was detected at lower concentrations in these cell culture samples compared to H2-expressing cells but higher than eGFP-expressing controls. Since transduced cells had similar expression levels of the downstream eGFP marker, lower levels of ⌬H2 suggest a potential reduction of antibody (Ab) affinity in the ELISA. Ab affinity to ⌬H2 relaxin appears to be ϳ33% of the affinity that the ELISA antibodies have for WT H2 (ϳ6 and 2 ng/mL of H2, and ⌬H2 were measured by ELISA, respectively; Fig. 2B ). Although the epitopes recognized by these Abs are not known (Elaine Unemori, BAS Medical, Inc., personal communication), these data suggest that the amino acid substitutions of ⌬H2 relaxin may have altered the epitope binding region. However, we also cannot discount the possibility that the ⌬H2 relaxin peptide has a reduced stability compared to H2 relaxin. As expected, 293T-⌬H2/eGFP(90%) CM samples had greater ⌬H2 relaxin levels compared to 293T-⌬H2/eGFP(50%) samples (Fig. 2B) .
Characterization of bioactivity of mutated H2 relaxin (⌬H2)
The in vitro THP-1 cAMP bioassay is a standard assay that measures bioactivity of relaxin-like peptides (15) . This assay confirmed that mutation of the relaxin RBD impairs the stimulatory capacity of the hormone (Fig.  2C ). PC3-Luc-H2/eGFP cells themselves were found to contain 13,221 Ϯ 4185 fmol/well total cAMP compared with PC3-Luc-⌬H2/eGFP (3,667Ϯ330 fmol/well) and PC3-Luc-eGFP (2,961Ϯ115 fmol/well) cultures (Fig.  2C) . THP-1 cells incubated with CM from PC3-Luc-H2/ eGFP cultures elicited a substantial increase in total cAMP from cultures (6,599Ϯ674 fmol/well) compared to basal levels elicited from CM samples of both PC3-Luc-⌬H2/eGFP (1,018Ϯ45 fmol/well) and PC3-LuceGFP (1,218Ϯ25 fmol/well).
293T cells stably-expressing human LGR7 exhibit a magnitude greater sensitivity to H2 relaxin compared to THP-1 cells (19) , likely due to the greater density of receptor presented on the cell surface (15) . Therefore, when 293T-LGR7 cells were subjected to a cAMP ELISA after stimulation with CM from LV-⌬H2/eGFP-transduced 293T cell cultures, a significant (Pϭ0.03) increase in cAMP of ϳ10% (1,074Ϯ46 fmol/well) was observed compared to CM from LV-eGFP-transduced 293T cell cultures (945Ϯ35 fmol/well; Fig. 2D ). This suggests that the ⌬H2 hormone retains modest signaling capacity for the LGR7 receptor.
Mutated H2 relaxin (⌬H2) exhibits antagonistic properties
Since ⌬H2 relaxin function was observed to be severely reduced while retaining some affinity for receptor binding, it was hypothesized that ⌬H2 (at high levels) may act as an antagonist and competitively inhibit H2 relaxin binding. Therefore, a THP-1 cAMP competitive assay was developed to measure the antagonistic properties of ⌬H2 relaxin (Fig. 3A) . Concentrated CM from LV-transduced 293T cells was used because these cells secrete high levels of WT H2 or ⌬H2 relaxins (as above). THP-1 cells were coincubated in 96-well plates with 0.4 ng rH2 and increasing CM volumes from LV-infected 293T cell cultures (from Fig. 2B ). When normalized to 293T-eGFP CM samples, 293T-⌬H2/ eGFP CM samples had a pronounced effect of reducing cAMP levels compared to control 293T-eGFP CM samples (Fig. 3A) . The addition of increasing volumes of 293T-⌬H2/eGFP CM samples (1, 3, and 6 l) resulted in greater suppression of total cAMP release from THP-1 cells. As expected, stimulation of THP-1 cells with 293T-H2/eGFP CM samples resulted in a dosedependent increase of cAMP release compared to the basal and reduced levels that were stimulated by 293T-eGFP and 293T-⌬H2/eGFP samples, respectively (Fig.  3A) . Taken together, these results suggest that the ⌬H2 hormone competes with rH2 for relaxin receptor binding on THP-1 cells.
Mutated H2 relaxin (⌬H2) binds to LGR7
A flow cytometry-based binding assay using 293T cells expressing human LGR7 receptors was developed for this (Fig. 3B,C) . Amounts of bH2 greater than 5 ng resulted in negligible differences in mean fluorescence intensity (Fig. 3B) . As controls, incubation with bH2 but not incubation with rH2 resulted in complete labeling of 293T-LGR7 cells (Fig. 3C) . Incubation with unconcentrated CM harvested from 293T-eGFP cells followed by addition of bH2 (5 ng) permitted 100% bH2 binding (Fig. 3C) . As expected, incubation with CM samples containing 1 or 4 ng/mL of WT H2 relaxin followed by competition with bH2 resulted in 93% and 98% retention (or 7% and 2% bH2 binding) of WT H2 relaxin. However, incubation with CM containing 1 ng/mL ⌬H2 relaxin followed by competition with bH2 resulted in the retention of ϳ19% of ⌬H2 binding (or 81% bH2 binding) that was significantly different (PϽ0.0001) compared to both eGFP control and WT H2 relaxin CM samples (Fig. 3C ). Taken together, these results suggest that the ⌬H2 hormone retains the capacity to bind to LGR7 receptor on 293T-LGR7 cells.
Effect of overexpression of ⌬H2 relaxin in two human prostate tumor models
To determine the effect of the overexpression of ⌬H2 relaxin in vivo, a prostate tumor model was chosen. PC3-Luc xenograft tumors were generated in NOD/ SCID mice. Compared with PC3-Luc-H2/eGFP tumors overexpressing WT H2 relaxin, PC3-Luc-⌬H2/eGFP tumors exhibited a significantly smaller tumor volume starting at week 6 (0.61-fold; PϽ0.05) until termination of the study at week 11 (0.56-fold; P Ͻ 0.02; Fig. 4A ). At week 6, PC3-Luc-H2/eGFP tumors exhibited significantly greater tumor volumes compared to PC3-LuceGFP tumors, in agreement with previous findings (12) . At weeks 10 and 11, PC3-Luc-⌬H2/eGFP tumors exhibited a significantly smaller tumor compared to both PC3-Luc-H2/eGFP and PC3-Luc-eGFP tumors.
One component of this study was to determine how long-term overexpression of H2 relaxin affects PC3-Luc tumor cell metastasis. In our previous study, we delivered 3.5 ϫ 10 6 tumor cells per NOD/SCID mouse, monitored tumor growth for up to 6 wk and observed no evidence of metastasis (12) . In the current study, we injected 2 ϫ 10 6 cells to allow prolonged relaxin expression before tumor size reached terminal endpoints, thereby permitting an extended opportunity for observation. At weeks 9 and 11, all animals were imaged for luciferase expression to 1) confirm general size of ⌬H2 relaxin exhibit high and low receptor affinity, respectively. Unconcentrated conditioned media containing WT H2 relaxin (1 and 4 ng/mL), ⌬H2 relaxin (1 ng/mL), or control medium were collected from LV-infected 293T clonal cell cultures, and applied to 293T-LGR7 cells before receptor binding was competed with bH2 (5 ng). Increasing amounts of 293T-⌬H2/eGFP CM had a consistent and significant effect of reducing cAMP levels compared to 293T-eGFP control samples, indicated at baseline "0". Increasing amounts of 293T-H2/eGFP concentrated conditioned medium resulted in a consistent and significant stimulation of cAMP levels compared to 293T-eGFP control samples. Experiments were performed in triplicate and repeated three times. *P Ͻ 0.05. B) Overlay histogram of 293T-LGR7 cells subjected to varying quantities of bH2 relaxin. 293T-LGR7 (5ϫ10 5 cells per sample) were incubated with 0, 5, 20, 50, or 100 ng of bH2 relaxin in PBS supplemented with 1% FCS for 15 min at RT, washed, and then stained with streptavidin-PE (1 mg/mL). C) Results of a flow cytometry-based binding assay using 293T-LGR7 cells demonstrates that WT H2 relaxin and mutated tumors as measured with calipers, and 2) assist in identifying PC3-Luc metastatic events. Figure 4B illustrates the location, size, and cell density proportionate to level of luciferase expression (12) of a tumor from representative animals from each PC3-Luc tumor group. This method of BLI confirms that PC3-Luc-H2/ eGFP, and PC3-Luc-eGFP tumors have significantly larger tumor volumes at weeks 9 and 11 compared to PC3-Luc-⌬H2/eGFP tumors. On termination of the study at week 11, putative metastatic tumors were harvested and imaged by BLI to confirm that the tissue originated from the PC3-Luc tumors (Fig. 4C) . Although not statistically significant, in animals bearing PC3-Luc-H2/eGFP tumors, 3 of 7 mice were found to have metastatic events compared to only 1 of 7 mice and 1 of 6 mice in the PC3-Luc-⌬H2/eGFP and PC3-Luc-eGFP groups, respectively. Tumors were also harvested and imaged for eGFP expression with a fluorescent stereomicroscope before tumor tissue processing (12) . Imaged tumors were confirmed to fluoresce from eGFP expression, due to the bicistronic format of the LV expression cassette. This indicates that H2 and ⌬H2 relaxins were also likely expressed because they are located upstream to the IRES element (see Fig. 1C ).
To demonstrate whether ⌬H2 relaxin overexpression had similar effects on other human prostate cancer models, LNCaP xenograft tumors were grown in NOD/SCID mice. From pilot studies, it was observed that tumors grown from this cell line, whether implanted in male or female NOD/SCID mice, never grew large enough for caliper measurement. Nonetheless, LNCaP-⌬H2/eGFP tumors (59.2Ϯ3.5 mg) exhibited a significantly lighter tumor weight after 14 wk in vivo compared to LNCaP-eGFP (72.9Ϯ5.2 mg; Pϭ0.05) and LNCaP-H2/eGFP (73.9Ϯ8.7 mg) tumors ( Table 1) . Similar to the PC3-Luc prostate tumor xenograft model, and although not statistically significant, mice bearing H2 relaxin-overexpressing tumors exhibited greater metastatic incidences (nϭ3/8) compared to mice bearing LNCaP-⌬H2/eGFP (nϭ1/8) and LNCaP-eGFP (nϭ1/8) tumors.
Mouse relaxins can bind to human LGR7
The flow cytometry-based binding assay we developed was employed to demonstrate that mouse relaxins can bind to human LGR7. CM containing either mouse relaxin or mouse relaxin-3 diluted either 1:2 or 1:5 (but not 1:20) resulted in LGR7 binding that was significantly greater (PϽ0.0001) than eGFP control samples (Fig. 5) . These results provide additional evidence to suggest that endogenous human H2 relaxin (secreted from PC3 tumor) and now mouse relaxins (secreted Representative BLI images of the same PC3-Luc-⌬H2/eGFP, PC3-Luc-eGFP, and PC3-Luc-H2/eGFP xenograft tumor-bearing mice at weeks 9 and 11. C) Metastatic tissues identified in animals were excised and imaged for luciferase expression to confirm origin from PC3-Luc prostate xenograft tumors. (Note: a representative metastatic tumor image from the PC3-Luc-H2/eGFP samples was used to illustrate the metastatic tumor found in a single mouse from the PC3-Luc-eGFP tumor-bearing mice.) T.I., tumor incidence; M.I., metastasis incidence; M.W., average mouse weight; n ϭ number of metastatic tumors found in respective animal. *P Ͻ 0.05. from host) have the capacity to contribute to LGR7-signaling and compete with recombinant H2 or ⌬H2 peptides for receptor binding in vivo.
Mutated H2 relaxin (⌬H2) modulates physiological parameters in vivo
In addition to measuring tumor growth, we investigated downstream pathways affected by H2 and ⌬H2 relaxin overexpression. The regulation of MMPs by relaxin in prostate tumors (12) and in other systems (21) has been reported. Gelatin zymography was used to detect the presence of gelatinase activity in tumor cell lysates. Gelatinase B (MMP-9) but not gelatinase A (MMP-2) activity was observed to be present in these samples by zymography. As shown in Fig. 6A , cell lysates analyzed from PC3-Luc-H2/eGFP tumors consistently exhibited lower levels of MMP-9 activity compared to PC3-LuceGFP (3.8-fold, Pϭ0.001). PC3-Luc-⌬H2/eGFP cell lysate samples appeared to exhibit intermediate levels of MMP-9 enzyme activity between PC3-Luc-eGFP (Pϭ0.066) and PC3-Luc-H2/eGFP (Pϭ0.16) samples, suggesting that ⌬H2 relaxin is affecting PC3-Luc signaling pathways responsible for MMP-9 expression.
In our previous study, the ability of H2 relaxin to promote angiogenesis was implicated as a potential mechanism for its role in facilitating tumor growth (12) . As an indicator of H2 relaxin's angiogenic role in the present tumors, VEGF isoform mRNA expression by RT-PCR, total tumoral vascularization measured by IHC staining of endothelial cells (ECs) with anti-mouse CD31 (PECAM-1), and MVA were examined (12) . Levels of VEGF transcript isoforms were present in greater levels within PC3-Luc-H2/eGFP tumors as shown by assay of individual and pooled samples from cDNA derived from each tumor within each treatment group compared to PC3-Luc-⌬H2/eGFP and PC3-LuceGFP samples (Fig. 6B) . Tumoral microvessel density (MVD) was also determined to be significantly greater (ϳ1.5-fold; PϽ0.05) in PC3-Luc-H2/eGFP tumors (24.3Ϯ4.4) compared to PC3-Luc-eGFP tumors (16.2Ϯ1.8) with an intermediate MVD (21.1Ϯ3) in PC3-Luc-⌬H2/eGFP tumors (Fig. 6C) . In addition, total MVAs averaged from sections of PC3-Luc-H2/eGFP tumors were significantly greater compared to the MVAs of PC3-Luc-⌬H2/eGFP (1.76-fold; Pϭ0.018) and PC3-Luc-eGFP (2.2-fold; Pϭ0.003) tumors (Fig. 6D) .
To determine whether H2 and ⌬H2 relaxins secreted from the PC3-Luc tumor xenografts elicited a systemic physiological response, plasma osmolality was measured from the animals at the termination of the study (Fig. 6E) . Plasma osmolality readings obtained from PC3-H2/eGFP, PC3-Luc-eGFP, and PC3-Luc-⌬H2/ eGFP tumor-bearing animals averaged 330 Ϯ 4.6, 339 Ϯ 5, and 342 Ϯ 4.6 mosmol/kg, respectively. PC3-Luc-⌬H2/eGFP animals exhibited significantly greater levels of plasma osmolality (12 mosmol/kg; Pϭ0.04) compared to PC3-Luc-H2/eGFP animals and only slightly greater levels compared to PC3-Luc-eGFP animals. These findings demonstrate that locally expressed ⌬H2 relaxin can have systemic effects.
The influence that H2 and ⌬H2 relaxins have on PC3-Luc tumor xenografts may be achieved at the level of signaling pathways between tumor and host. Indeed, LGR7 receptor was detected by RT-PCR at equal levels from pooled cDNA samples taken from each treatment group (Fig. 6F) .
To determine whether the influence of H2 and ⌬H2 relaxins on PC3-Luc cell growth can occur in the absence of in vivo signals, an in vitro soft agarose colony assay was used. After 5 wk in culture, PC3-Luc colony spheres were counted, measured, and imaged (Fig.  6G) . No apparent size differences were observed between the PC3-H2/eGFP, PC3-Luc-⌬H2/eGFP, and PC3-Luc-eGFP colony spheres (data not shown). This suggests that the differences in tumor growth in NOD/ SCID mice are likely due to angiogenic or other in vivo signaling pathways, which are not assessed by this in vitro assay.
Intratumoral delivery of LV-⌬H2/eGFP suppresses tumor growth
To continue our investigation into the biological nature of ⌬H2 relaxin, LVs were delivered intratumorally to mice over an 18-day period. During the first 7 days, LV-⌬H2/eGFP-injected tumors exhibited a significant impairment of growth (131Ϯ25.3 mm
3 ) compared to LV-H2/eGFP (199Ϯ20.3 mm 3 ; Pϭ0.04) and LV-eGFPinjected (195Ϯ20.7 mm 3 ; Pϭ0.05) tumors (Fig. 7A) . Thereafter, LV-⌬H2/eGFP-injected tumors displayed moderately suppressed tumor volumes compared to tumors receiving LV-H2/eGFP or LV-eGFP. At the end of the study, animals were imaged (as above) to measure tumor size, density, and location. Figure 7B shows LGR7 using a flow cytometry-based binding assay. Conditioned media containing mouse relaxin or mouse relaxin-3 were collected from LV-transduced 293T cell cultures (19) , and applied to 293T-LGR7 cells (in several dilutions) before receptor binding was competed with bH2 (10 ng). Results demonstrate that mouse relaxins exhibit high LGR7 relaxin receptor affinity compared to null binding with eGFP control samples. Experiments were performed in quadruplicate and repeated at least twice. RLN1, mouse relaxin; RLN3, mouse relaxin-3; NT, eGFP controls; H2, human H2 relaxin; r ϭ recombinant human H2 relaxin; b ϭ biotinylated recombinant human H2 relaxin. *P Ͻ 0.05.
an image of representative animals from each group, illustrating the apparent tumor suppression observed in mice bearing LV-⌬H2/eGFP-injected tumors. To confirm that the tumor cells were LV-transduced (i.e., positive for eGFP expression), tumors were harvested and imaged under a fluorescent stereomicroscope (Fig.  7C) . Compared to PBS-injected controls, LV-treated mice had regions positive for eGFP expression within the tumor (ϫ0.8 magnification) . At ϫ10 magnification, clusters of transduced cells present at the LV injection sites on the tumor can be distinguished.
DISCUSSION
H2 relaxin displays cross-reactivity for two leucinerich repeat (LRR)-containing G-protein coupled receptors (GPCR) named LGR7 and LGR8 (18). Halls et al. (22) proposed a model that relaxin binds in a two-stage process to both a primary high-affinity binding site located on the ectodomain of the LRR and a lower affinity binding site located within the transmembrane region. The high-affinity binding site couples to cAMP signaling with high efficiency, whereas the low-affinity site couples with lower efficiency (22) . Further work in that study showed that relaxin-like peptides can bind to the low-affinity transmembrane site without binding to the primary high-affinity site. That said, peptide binding to the lower-affinity region likely results in null or suboptimal signal transduction without engagement of the high-affinity region (22) .
On the basis of the above mentioned work (22) and the evidence reported in the current study, it is likely that the partial mutation of the RBD of H2 relaxin (⌬H2) permits the retention of some level of receptor affinity (possibly at the lower-affinity region), while exhibiting significantly impaired function. It is possible that at high concentrations, ⌬H2 relaxin is able to bind to LGR7 and LGR8 receptors without eliciting a significant cAMP-mediated signal transduction cascade. Varying affinities of relaxin-like peptides to LGR7 and LGR8 receptors have suggested that amino acid composition and ligand structure influences the degree of receptor binding and activation (22) . Therefore, the substitution of the B13 and B17 arginines for lysine residues (while leaving the isoleucine at B20 intact) may be sufficient to render the mutated H2 form (⌬H2) with antagonistic properties by inducing subtle conformational changes that compromise its full capacity for receptor binding and signaling.
Two assays measuring either peptide biological activity or binding capabilities demonstrated that ⌬H2 relaxin does retain reduced affinity for the receptor albeit with significantly impaired signaling function. In a competition assay measuring H2 relaxin-induced cAMP release from THP-1 cells, ⌬H2 secreted from LV-infected 293T cell cultures competed with rH2 hormone (0.4 ng) for receptor binding (Fig. 3A) . As the ratio of ⌬H2:rH2 increased in each sample (with increasing sample volume), greater suppression of secreted cAMP levels from THP-1 cells compared to eGFP controls was observed. A second assay using flow cytometry was designed to measure receptor binding affinity of ⌬H2. This assay permits a rapid, cost-effective, and sensitive characterization of the receptor binding properties of relaxin-like peptides. The assay relies on the abilities of conjugate-labeled rH2 to displace receptor-bound relaxin-like peptides. In the current study, ⌬H2 relaxin exhibited modest binding to the relaxin receptor on 293T-LGR7 cells compared to uninhibited binding of WT H2 relaxin. Because ⌬H2 relaxin retains receptorbinding affinity, while exhibiting significantly impaired signaling capacity, ⌬H2 relaxin can function as a relaxin receptor antagonist when present in molar excess.
The antagonistic properties of the ⌬H2 hormone were also demonstrated in vivo in three distinct animal models. We observed that LV-engineered overexpression of ⌬H2/eGFP results in impaired prostate tumor xenograft growth compared to tumors overexpressing WT H2/eGFP or control tumors overexpressing eGFP. It can be theorized that tumor-expressed ⌬H2 relaxin is neutralizing available receptors in an autocrine fashion, thereby competing with endogenous relaxins for receptor binding and blocking endogenous H2 signaling. Indeed, we showed that mouse relaxin and mouse relaxin-3 are capable of binding to human LGR7 (Fig.  5) . Therefore, ⌬H2 relaxin may be competing with human H2 relaxin secreted from PC3 tumors and/or mouse relaxins circulating in the host. At the same time, however, we cannot discount the possibility that ⌬H2 relaxin may exhibit preferential and/or partial affinity for one receptor (i.e., LGR7, LGR8, or other), thereby selecting for a receptor-specific signaling cascade. The precise pathways that LGR7 and LGR8 may regulate to facilitate tumor growth are not known, but an antagonist may abrogate endogenous H2-mediated pathways altering cellular proliferation, gene expression, and neoangiogenesis (23) .
Although ⌬H2 relaxin exhibited significant antagonistic function, it also displayed evidence of an ability to elicit modest signaling both in vitro and in vivo. This observation allows one to infer that in our systems, leaky relaxin signaling is observed because the H2 analog is likely not completely neutralizing all available relaxin receptors and is exhibiting modest signal transduction. For example, the putative antagonistic activity demonstrated by ⌬H2 relaxin was evidenced by intermediate levels of MMP-9 activity (an established downstream effector in H2 relaxin signaling) and MVD in ⌬H2 relaxin-expressing tumors compared to values derived from H2/eGFP and eGFP-expressing tumors ( Fig. 6A,C; ref. 12 ). Taken together, the ⌬H2 relaxin analog appears to be partially interfering with the endogenous functions of H2 relaxin in PC3-Luc tumors by acting on relaxin receptors to alter cellular signaling pathways. Future studies will be required to dissect the differential aspects on a molecular level.
In the current study, changes in plasma osmolality were also investigated as an approach to measure the paracrine influence of tumor-secreted ⌬H2 relaxin. Relaxin knockout (RLXϪ/Ϫ) mice exhibit a phenotype with an increased plasma osmolality of 10 mosmol/kg water compared to WT mice (24) . On the contrary, delivery of human H2 relaxin i.v. or i.c.v. in the rat causes reductions in plasma osmolality (25, 26) . We observed that plasma osmolality readings were ϳ12 mosmol/kg higher in animals with ⌬H2-expressing tumors compared to WT H2-expressing tumors (Pϭ0.04). This suggests that ⌬H2 may be blocking endogenous ligand binding to relaxin receptors in the mouse (i.e., pituitary gland, kidney, or other regions) and thereby affecting osmoregulation.
The mechanism behind ⌬H2-mediated suppression as evidenced in the current study, may operate by interfering with signals shared between host and tumor because no differences were observed in vitro between PC3-Luc soft agarose spheroid colony sizes (Fig. 6F ) and cell proliferation (data not shown).
However, distinct differences of MVD and MVA between treatment groups suggest that ⌬H2 relaxin may be affecting pathways of angiogenesis. PC3-Luc-H2/eGFP tumors had ϳtwo-fold greater MVA compared to PC3-Luc-⌬H2/eGFP and PC3-Luc-eGFP tumors (Fig. 6D ). This suggests that H2 relaxin may have a role in prostate tumor growth not just by enhancing vascularization (12) , but also by vasodilation, thereby increasing tumoral blood flow. Therefore, overexpression of ⌬H2 relaxin in the tumor microenvironment may inhibit endogenous H2 relaxin progrowth signals to tumor cells or tumor-infiltrated ECs (5), impairing biochemical pathways involving angiogenesis (2, 12) , vasodilation (27) , cell proliferation, and apoptosis (2, 3, 28) .
We previously reported a study showing that overexpression of H2 relaxin from PC3 tumors leads to greater tumor growth up to 6 wk in NOD/SCID male mice (12) . At week 6, an advanced angiogenic phenotype was observed in the H2/eGFP-overexpressing tumors compared to the eGFP control tumors (12) . In the current study, while PC3-Luc-H2/eGFP and PC3-Luc/eGFP tumors did not differ in size after week 6, ⌬H2 relaxin-expressing tumors maintained a suppressed tumor volume for the 11 wk study period (Fig.  4A ). In addition, tumors treated by intratumoral delivery of LV-⌬H2/eGFP exhibited impaired tumor growth only up to 1 wk. It is possible that after this time period in this model, tumor growth overcomes any ⌬H2-induced impairment. Therefore, in combination with our previous findings (12), a hypothesis can be proposed that H2 relaxin expression can provide prostate tumors with an advantage for early tumorigenesis (up to week 6) mediated by angiogenic and/or other pathways. After this time period, other tumoral compensatory mechanisms may play a role in facilitating tumor growth.
Tumor development is a multistep process that involves signaling from a number of pathways. Considering that H2 relaxin is a pleiotropic hormone (2-5) with functions in angiogenesis, blood flow, and pressure, ECM remodeling, cellular proliferation, and apoptosis, it is a desirable target that, if blocked, could demonstrate moderate antagonistic efficacy in both in vitro and in vivo systems. To date, no H2 relaxin peptide antagonists have been described in the literature; however, the LGR7 relaxin receptor ectodomains were demonstrated to bind relaxin, inhibit receptor-mediated signaling of cAMP, and suppress nipple development in mice (18) . Recently, the systematic truncation of amino acids from the N terminus of relaxin-like factor resulted in the discovery of peptides that exhibit antagonistic-like properties by suppressing cAMP signaling (29, 30) . The H2 relaxin analog described in the present study offers the potential to inhibit H2 relaxin signaling at the receptor presented on the cell surface.
Because H2 relaxin has not been attributed an essential role in the physiological function of humans (2), systemic delivery of recombinant ⌬H2 relaxin to potentially curb tumor growth can be conceivable, considering that H2/LGR7 or H2/LGR8 signaling axes may be temporarily dispensable. In addition, because relaxin has been implicated in several other types of neoplasias (6 -8) , further modifications of the RBD within H2 relaxin and other relaxin-like peptides may also offer utility for other cancers.
